Chronic hepatitis B infection in a hepatology clinic at a university hospital in Jeddah

Fallatah, Hind I; Akbar, Hisham O.

doi:10.3855/jidc.751

Cited by 2 publications

(1 citation statement)

References 38 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberra et al (2017) 12 Aberra et al (2017) 12 Aberra et al (2017) 12 Aberra et al (2017) 12 Al-Naamani et al (2013) 15 Coppola et al (2017) 51 Cotler et al (2009) 52 Cuomo et al (2016) 55 De Vroey et al (2013) 59 Deltenre et al (2012) 60 Ding et al (2013) 63 Fallatah et al (2010) 71 Fung et al (2011) 76 Fung et al (2011) 76 Milosevic et al (2013) 118 Pérez-Molina et al (2011) 129 Spradling et al (2013) 142 Stefos et al (2009) 143 Stroffolini et al (2012) 146 Subramaniam et al (2012) 147 Tedder et al (2013) 152 Vella et al (2012) 158 Widjaja et al (2007) 160 Yuen et al (2009) 169…”

Section: Weight (%) Proportion (95% Ci)mentioning

confidence: 99%

Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis

Tan

Bhadoria

Cui³

et al. 2021

The Lancet Gastroenterology & Hepatology

116

View full text Add to dashboard Cite

Summary Background In 2016, of the estimated 257 million people living with chronic hepatitis B virus (HBV) infection worldwide, only a small proportion was diagnosed and treated. The insufficiency of information on the proportion of people infected with HBV who are eligible for treatment limits the interpretation of global treatment coverage. We aimed to estimate the proportion of people with chronic HBV infection who were eligible for antiviral treatment worldwide, based on the WHO 2015 guidelines. Methods In this systematic review and meta-analysis, we searched Medline, EMBASE, and the Cochrane databases from Jan 1, 2007, to Jan 31, 2018, for studies describing HBsAg-positive people in the population or health-care facilities. We extracted information from published studies using a standardised form to estimate the frequency of cirrhosis, abnormal alanine aminotransferase (ALT), HBV DNA exceeding 2000 IU/mL or 20 000 IU/mL, presence of HBeAg, and eligibility for treatment as per WHO and other guidelines as reported in the studies. We pooled proportions through meta-analysis with random effects. The study was registered with PROSPERO, CRD42020132345. Findings Of the 13 497 studies, 162 were eligible and included in our analysis. These studies included 145 789 participants. The pooled estimate of the proportion of cirrhosis was 9% (95% CI 8–10), ranging from 6% (4–8) in community settings to 10% (9–11) in clinic settings. Examining the proportion of participants who had characteristics used to determine eligibility in the WHO guidelines, 1750 (10·1%) of 17 394 had HBV DNA exceeding 20 000 IU/mL, and 20 425 (30·8%) of 66 235 had ALT above the upper limit of normal. 32 studies reported eligibility for treatment according to WHO or any other guidelines, with a pooled estimate of eligibility at 19% (95% CI 18–20), ranging from 12% (6–18) for studies in community settings to 25% (19–30) in clinic settings. Interpretation Many studies described people with HBV infection, but few reported information in a way that allowed assessment of eligibility for treatment. Although about one in ten of the 257 million people with HBV infection (26 million) might be in urgent need of treatment because of cirrhosis, a larger proportion (12–25%) is eligible for treatment in accordance with different guidelines. Future studies describing people with HBV infection should report on treatment eligibility, according to broadly agreed definitions. Funding WHO and US Centers for Disease Control and Prevention.

show abstract